About Martin Babler
Martin Babler is a director at MapLight Therapeutics.
Form D filings name Martin Babler as CEO and director at Alumis.
Martin Babler reports to the SEC as a director or officer of 9 public companies, including Prelude Therapeutics (PRLD), Alumis (ALMS) and 89bio (ETNB).
Martin Babler first appears on SEC filings in 2008.
Experience
This experience comes from SEC filings. The years are when the filings name Martin Babler in the role, so the role may have started earlier or lasted longer.
MI
PI
Prelude Therapeutics Inc
Director
2021 – 2026 · Public company (PRLD)
8I
89bio, Inc.
Director
2024 – 2025 · Public company (ETNB)
NI
Neurogene Inc.
Director
2020 – 2023 · Public company (NGNE)
OS
Omega Alpha SPAC
Director
2021 · Public company (OMEG)
PI
Principia Biopharma Inc.
President, CEO and director
2018 – 2020 · Public company (PRNB)
ZI
ZS Pharma, Inc.
Director
2015 · Public company (ZSPH)
II
Infinity Pharmaceuticals, Inc.
Director
2008 – 2013 · Public company (INFI)
Key Colleagues at Startups
The people Martin Babler works with at each company, as listed on that company's latest Form D.
Alumis Inc. · Form D, Jul 24, 2024
SA
Srinivas Akkaraju
Director
JS
John Schroer
Executive officer
JT
James Tananbaum
Director
DR
Derrick Richardson
Executive officer
PM
Patrick Machado
Director
SS
Sapna Srivastava
Director
MB
Mark Bradley
Executive officer
ZY
Zhengbin Yao
Director
SK
Sara Klein
Executive officer
DG
David Goldstein
Executive officer
JD
Jorn Drappa
Executive officer
AC
Alan Colowick
Director
RH
Roy Hardiman
Executive officer